The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Capital infusion to accelerate Earendil’s R&D platform
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
The endorsement follows overwhelming support for the share swap preceding the merger,
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
The Silver Medal recognizes strong performance across sustainability, ethics, environment, labour & human rights, and responsible procurement
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
Subscribe To Our Newsletter & Stay Updated
